1-苄基-3-(4-溴苯基)脲 | 13208-62-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-苄基-3-(4-溴苯基)脲
• 英文名称: 1-benzyl-3-(4-bromophenyl)urea
• 英文别名: N-benzyl-N'-(4-bromophenyl)urea；N-Benzyl-N'-(4-brom-phenyl)-harnstoff
• CAS: 13208-62-3
• 化学式: C₁₄H₁₃BrN₂O
• mdl: MFCD00017794
• 分子量: 305.174
• InChiKey: BTYUPTJAFCJIHQ-UHFFFAOYSA-N

物化性质

• 沸点：
  407.9±45.0 °C(Predicted)
• 密度：
  1.465±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  4-吡唑硼酸频哪醇酯 、 1-苄基-3-(4-溴苯基)脲 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 2.0h， 生成 1-(4-(1H-pyrazol-4-yl)phenyl)-3-benzylurea
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Urea Derivatives as Highly Potent and Selective Rho Kinase Inhibitors

  摘要：

  RhoA and its downstream effector ROCK mediate stress fiber formation and cell contraction through their effects on the phosphorylation of myosin light chain (MLC). Inhibition of the RhoA/ROCK pathway has proven to be a promising strategy for several indications such as cardiovascular disease, glaucoma, and inflammatory disease. In 2010, our group reported urea-based ROCK inhibitors as potential antiglaucoma agents. These compounds showed potent IC50 values in enzymatic and cell-based assays and significant intraocular pressure (IOP)-lowering effects in rats (similar to 7 mmHg).(22) To develop more advanced ROCK inhibitors targeting various potential applications (such as myocardial infarction, erectile dysfunction, multiple sclerosis, etc.) in addition to glaucoma, a thorough SAR for this urea-based scaffold was studied. The detailed optimization process, counter-screening, and in vitro and in vivo DMPK studies are discussed. Potent and selective ROCK inhibitors with various in vivo pharmacokinetic properties were discovered.

  DOI：

  10.1021/jm400062r
• 作为产物：
  描述：

  异氰酸苯酯 在 1,3,5-三溴-1,3,5-噻嗪烷-2,4,6-三酮 作用下， 以 正己烷 、 乙腈 为溶剂， 生成 1-苄基-3-(4-溴苯基)脲
  参考文献：
  名称：

  三卤代异氰尿酸对不对称N-苄基和N-苯基脲的高效直接卤化反应

  摘要：

  摘要 在室温下，使用三卤异氰尿酸在乙腈中开发了一种简单有效的方法，用于直接卤化N-苯基脲。该方案被证明对于构建具有不同取代模式的N-苯基脲是有效的。另外，在室温下，在三氟乙酸和乙腈的混合物存在下，将反应性较低的N-苄基脲卤化。 在室温下，使用三卤异氰尿酸在乙腈中开发了一种简单有效的方法，用于直接卤化N-苯基脲。该方案被证明对于构建具有不同取代模式的N-苯基脲是有效的。另外，在室温下，在三氟乙酸和乙腈的混合物存在下，将反应性较低的N-苄基脲卤化。

  DOI：

  10.1055/s-0036-1589149

文献信息

• [EN] UREA AND CARBAMATE COMPOUNDS AND ANALOGS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS D'URÉE ET DE CARBAMATE ET ANALOGUES UTILISÉS COMME INHIBITEURS DE KINASE
  申请人：FENG YANGBO

  公开号：WO2010036316A1

  公开（公告）日：2010-04-01

  The invention is directed to compounds that can inhibit the bioactivity of one or more kinases such as any of Rho kinases, PKB (Akt) kinases, p70S6K kinase, LIM kinases, or IKK kinases, to methods of use of those compounds, and to methods of preparation of those compounds The inventive compounds can be used In the treatment of a variety of medical malconditions.

  该发明涉及可以抑制一个或多个激酶的生物活性的化合物，如Rho激酶、PKB（Akt）激酶、p70S6K激酶、LIM激酶或IKK激酶中的任何一个，以及这些化合物的使用方法和制备方法。这些创新的化合物可用于治疗各种医疗疾病。
• 一种合成N，N’-二取代基脲的方法
  申请人：南京理工大学

  公开号：CN103664704B

  公开（公告）日：2016-05-18

  本发明公开了一种合成N,N’-二取代基脲的新方法，在反应容器中，加入N-取代基脲、金属铱、铑或钌络合物催化剂、碱、化合物醇和溶剂（或不加溶剂）；反应混合物在90-130oC下反应数小时后，冷却到室温；旋转蒸发除去溶剂，然后通过柱分离，得到目标化合物。同现有技术相比，本发明从商品化或容易合成的N-取代基脲出发，通过和醇发生区域选择性烷基化反应，得到的N,N’-二取代基脲，反应展现出三个显著的优点：1）使用近于无毒的醇为烷基化试剂；2）反应只生成水为副产物，无环境危害；3）反应原子经济性高；因此，该反应符合绿色化学的要求，具有广阔的发展前景。
• Sah, Journal of the Chinese Chemical Society (Peking), 1946, vol. 13, p. 22,26,27
  作者：Sah

  DOI：——

  日期：——
• Discovery of Potent and Selective Urea-Based ROCK Inhibitors and Their Effects on Intraocular Pressure in Rats
  作者：Yan Yin、Michael D. Cameron、Li Lin、Susan Khan、Thomas Schröter、Wayne Grant、Jennifer Pocas、Yen Ting Chen、Stephan Schürer、Alok Pachori、Philip LoGrasso、Yangbo Feng

  DOI：10.1021/ml1000382

  日期：2010.7.8

  A series of urea-based Rho kinase (ROCK) inhibitors were designed and evaluated. The discovered compounds had excellent enzyme and cellular potency, high kinase selectivity, high aqueous solubility, good porcine corneal penetration, and appropriate DMPK profiles for topical applications as antiglaucoma therapeutics.
• Synthesis and Biological Evaluation of Urea Derivatives as Highly Potent and Selective Rho Kinase Inhibitors
  作者：Yan Yin、Li Lin、Claudia Ruiz、Susan Khan、Michael D. Cameron、Wayne Grant、Jennifer Pocas、Nibal Eid、HaJeung Park、Thomas Schröter、Philip V. LoGrasso、Yangbo Feng

  DOI：10.1021/jm400062r

  日期：2013.5.9

  RhoA and its downstream effector ROCK mediate stress fiber formation and cell contraction through their effects on the phosphorylation of myosin light chain (MLC). Inhibition of the RhoA/ROCK pathway has proven to be a promising strategy for several indications such as cardiovascular disease, glaucoma, and inflammatory disease. In 2010, our group reported urea-based ROCK inhibitors as potential antiglaucoma agents. These compounds showed potent IC50 values in enzymatic and cell-based assays and significant intraocular pressure (IOP)-lowering effects in rats (similar to 7 mmHg).(22) To develop more advanced ROCK inhibitors targeting various potential applications (such as myocardial infarction, erectile dysfunction, multiple sclerosis, etc.) in addition to glaucoma, a thorough SAR for this urea-based scaffold was studied. The detailed optimization process, counter-screening, and in vitro and in vivo DMPK studies are discussed. Potent and selective ROCK inhibitors with various in vivo pharmacokinetic properties were discovered.